Edesa Biotech, Inc. (EDSA)

In the past six months, Edesa Biotech's stock has experienced several notable events. In February 2026, positive results from the Phase 3 paridiprubart study led to a stock price increase of 67.96%, and the company reported its Fiscal 1st Quarter 2026 results. In December 2025, the company reported its Fiscal Year 2025 results, followed by a -16.09% change in stock price. In October 2025, the announcement of its upcoming conference schedule resulted in a -6.45% change. In March 2026, the company announced it is advancing its vitiligo program for planned mid-2026 enrollment, with the stock price decreasing by -10.81%. In April 2026, Edesa Biotech was invited for an oral showcase at the Respiratory Innovation Summit, leading to a +6.12% increase. Over the past year, the stock has seen a 144.93% change, with a 52-week range between $0.72 and $9.37. As of April 8, 2026, the share price was $5.96, an increase of 170.91% from April 9, 2025, when it was $2.20 per share.

The demand for Edesa Biotech's products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the progression of its drug candidates through clinical trials, regulatory approvals, and the prevalence of the diseases they aim to treat. The success of clinical trials and the unmet medical needs in these areas are the primary factors influencing potential future demand for its therapies.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, manufacturing, and commercializing pharmaceutical products for inflammatory and immune-related diseases. The company's pipeline includes EB05 (paridiprubart), a monoclonal antibody in Phase 3 clinical study for ARDS, which has received funding from the Government of Canada. EB01 (1.0% daniluromer cream) is a topical non-steroidal anti-inflammatory compound that has completed a Phase 3 clinical study for chronic Allergic Contact Dermatitis. EB06 is an anti-CXCL10 monoclonal antibody candidate being developed for vitiligo, with a planned Phase 2 clinical study. EB07 is a monoclonal antibody in a Phase 2 clinical study for pulmonary fibrosis.

Edesa Biotech, Inc. is headquartered in Markham, Ontario, Canada, and its common shares are listed on the Nasdaq Stock Market under the ticker symbol EDSA.

Edesa Biotech maintains a reputation as a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and immune-related diseases, particularly those with significant unmet medical needs. Events that have positively impacted its reputation include reporting additional positive results from its Phase 3 paridiprubart study, advancing its vitiligo program towards a planned Phase 2 clinical study, receiving invitations to present at significant industry events, and its paridiprubart program receiving two funding awards from the Government of Canada.

Approximately 35.94% of Edesa Biotech's stock is owned by institutional investors, 18.86% by insiders, and 45.20% by public companies and individual investors. Major institutional owners and shareholders include Rubric Capital Management LP, Stonepine Capital Management, LLC, Velan Capital Investment Management LP, Nantahala Capital Management, LLC, DRW Securities, LLC, Diadema Partners Lp, Citadel Advisors Llc, Geode Capital Management, Llc, Vanguard Group Inc, and State Street Corp. Pardeep Nijhawan owns the most shares among individual investors.